<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038970</url>
  </required_header>
  <id_info>
    <org_study_id>KN019-201</org_study_id>
    <nct_id>NCT04038970</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</brief_title>
  <official_title>A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KN019 in Patients With Active Rheumatoid Arthritis While Receiving Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, pharmacokinetics, safety, and
      immunogenicity of KN019 after intravenous administration on background methotrexate in
      patients with active rheumatoid arthritis and inadequate response to methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to provide efficacy data in support of the proposed claims of reducing
      signs and symptoms, improvement in physical function, and 1 year safety data for KN019 dosed
      at 5 and 10 mg/kg in patients with inadequate response to stable weekly doses of background
      methotrexate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants the proportion of subjects meeting the American College of Rheumatology criteria for 20% improvement (ACR 20) on Day 169</measure>
    <time_frame>At Day 169</time_frame>
    <description>The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>KN019 5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KN019 10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KN019, 5mg/kg</intervention_name>
    <description>Solution, intravenous, 5 mg/kg</description>
    <arm_group_label>KN019 5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KN019, 10 mg/kg</intervention_name>
    <description>Solution, intravenous, 10 mg/kg</description>
    <arm_group_label>KN019 10mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution, intravenous, Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition</description>
    <arm_group_label>KN019 10mg/kg</arm_group_label>
    <arm_group_label>KN019 5mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  The patient must meet the American College of Rheumatology (ACR) classification
             criteria for the diagnosis of rheumatoid arthritis (RA) by satisfying at least four of
             the seven criteria;

          -  Patients must have been taking methotrexate for at least 3 months with at least a
             weekly dose of 7.5-25 mg, and a stable dose for 28 days prior to treatment (Day 1)

          -  The patient must have active disease at both screening and baseline, as defined by
             having both:

             6 tender/painful joints on motion (out of 68 joints assessed); and; 6 swollen joints
             (out of 66 joints assessed); CRP ≥ 7 mg/L, or ESR ≥28 mm/h

        Key Exclusion Criteria:

          -  Pregnant or lactating females.

          -  History of any other autoimmune rheumatic disease.

          -  Patients who have previously received CTLA4-Ig therapy for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian kang Hu, Doctor</last_name>
    <phone>13879936380</phone>
    <phone_ext>+86</phone_ext>
    <email>hjk0799@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pingxiang people's hospital</name>
      <address>
        <city>PingXiang</city>
        <state>Pingxiang</state>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Kang Hu, Doctor</last_name>
      <phone>13879936380</phone>
      <phone_ext>+86</phone_ext>
      <email>hjk0799@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

